Last C$0.38 CAD
Change Today -0.005 / -1.30%
Volume 20.5K
MBX On Other Exchanges
Symbol
Exchange
Toronto
OTC US
Frankfurt
As of 3:59 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

microbix biosystems inc (MBX) Snapshot

Open
C$0.40
Previous Close
C$0.39
Day High
C$0.40
Day Low
C$0.37
52 Week High
01/23/14 - C$0.57
52 Week Low
07/24/13 - C$0.12
Market Cap
26.0M
Average Volume 10 Days
72.7K
EPS TTM
C$0.01
Shares Outstanding
68.5M
EX-Date
--
P/E TM
34.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for MICROBIX BIOSYSTEMS INC (MBX)

Related News

No related news articles were found.

microbix biosystems inc (MBX) Related Businessweek News

No Related Businessweek News Found

microbix biosystems inc (MBX) Details

Microbix Biosystems Inc., a biotechnology company, develops, manufactures, and sells biological products and technologies in North America, Europe, and internationally. The company provides cell culture based infectious disease products; and licenses cell culture based technologies, as well as is involved in the contract development work in microbiology. It also offers infectious disease antigens, such as viral, bacterial, and parasitic products used in various applications, including immunodiagnostic assays; basic and applied research in virology, microbiology, cell biology, molecular biology, immunology, and pathology; as controls and calibrators for a range of medical devices; and for vaccine and antiviral research and development. In addition, the company provides adenovirus vectors, cells, and services to biopharmaceutical and biotechnology researchers and companies. The company develops various biological technologies, including VIRUSMAX, a vaccine manufacturing technology; LumiSort, a semen sexing technology; and Kinlytic, a thrombolytic drug. It serves medical diagnostic and biotechnology industries. The company was founded in 1988 and is headquartered in Mississauga, Canada.

Founded in 1988

microbix biosystems inc (MBX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$212.4K
Founder, Executive Chairman and Member of Hum...
Total Annual Compensation: C$197.3K
Chief Financial Officer
Total Annual Compensation: C$14.1K
Senior Vice President of Sales & Business Dev...
Total Annual Compensation: C$177.5K
Vice President of Biotherapeutics
Total Annual Compensation: C$153.0K
Compensation as of Fiscal Year 2013.

microbix biosystems inc (MBX) Key Developments

Microbix Biosystems Inc. Expands Customer Agreement to Approximately $17 Million over 5 Years

Microbix Biosystems Inc. announced that it has reached an agreement with an existing, long-term customer to supply significantly increased antigen volumes. Customers use Microbix' infectious disease antigens in their diagnostic test kits, which they sell to laboratories and hospitals globally. This customer has secured incremental business for their infectious disease tests and, as a result, requires more antigen supply from Microbix. This agreement represents an annual sales increase of more than $2 million. Shipments are expected to commence in the next fiscal quarter.

Microbix Biosystems Inc. Reports Earnings Results for the First Quarter Ended December 31, 2013

Microbix Biosystems Inc. reported earnings results for the first quarter ended December 31, 2013. In the first quarter, Microbix reported revenue of $1,927,885, more than double the revenue of $904,413 for the same period in 2013. The higher revenue was primarily due to continued growth in customer demand for virology products including significant new business from an existing customer, as well as a favourable currency impact. Operating income for the first quarter was $214,406 compared to a loss of $629,505 for the same quarter last year. Net income was $116,161 or $0.002 per share against loss of $629,505 or $0.010 per share a year ago. Cash flow was $51,773 against $53,743 a year ago.

Novartis AG Fails to Invalidate Patent Claims against Microbix Biosystems

Microbix Biosystems Inc. announced that it has successfully defended all of its VIRUSMAX patent claims against a challenge by Novartis at a hearing at the European Patent Office (EPO) in Munich, Germany. Novartis Vaccines and Diagnostics challenged Microbix' invention of its manufacturing process trademarked VIRUSMAX, on several grounds. The EPO Tribunal agreed with Microbix' position and ruled that all claims are novel and inventive. Microbix therefore retains all of its patent claims as originally granted.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MBX:CN C$0.38 CAD -0.005

MBX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MBX.
View Industry Companies
 

Industry Analysis

MBX

Industry Average

Valuation MBX Industry Range
Price/Earnings 31.9x
Price/Sales 2.8x
Price/Book 4.1x
Price/Cash Flow 32.7x
TEV/Sales 2.2x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MICROBIX BIOSYSTEMS INC, please visit www.microbix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.